We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Guardant Health, OncoMed Collaborate
News

Guardant Health, OncoMed Collaborate

Guardant Health, OncoMed Collaborate
News

Guardant Health, OncoMed Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Guardant Health, OncoMed Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Guardant Health and OncoMed Pharmaceuticals have announced collaboration on an immunoncology clinical trial. The companies have developed a custom-designed blood test based on Guardant Health's liquid biopsy technology to look for biomarkers relevant for an anti-RSP03 antibody OncoMed has developed.

Expression of the RSP03 gene, including fusions involving the gene, have been shown to drive tumor growth in several cancer subsets including ovarian, lung, and pancreatic. The clinical trial of the compound will enroll patients with advanced solid tumors whose tumors over express RSP03. In a Phase 1b portion of the trial, OncoMed will analyze the anti-RSP03 compound with chemotherapy in second-line colorectal cancer patients.

"Patients with RSPO3 fusions are thought to have particularly poor outcomes," Guardant CEO Helmy Eltoukhy said in a statement. "Helping OncoMed better identify the patients most likely to respond to anti-RSPO3 without requiring a biopsy is an exciting opportunity to apply our technology where the potential to improve patient prognosis and outcomes is so great."

"Partnering with Guardant Health to identify biomarker-selected patients with a simple, accurate blood test for our ongoing Phase 1a/1b clinical trial will increase our chances of including patients who may benefit from treatment with this investigational agent and will enable us to gain a better understanding of anti-RSPO3's clinical potential earlier in its development," Ann Kapoun, OncoMed's vice president of translational medicine, said in a statement.

Advertisement